Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
A. Marani, H. Gioacchini, M. Paolinelli, A. Offidani & A. Campanati. (2023) Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma. Expert Opinion on Drug Metabolism & Toxicology 19:8, pages 555-567.
Read now
Read now
Articles from other publishers (7)
I. Anestopoulos, S. Kyriakou, V. Tragkola, I. Paraskevaidis, E. Tzika, M. Mitsiogianni, M.V. Deligiorgi, G. Petrakis, D.T. Trafalis, S. Botaitis, A. Giatromanolaki, M.I. Koukourakis, R. Franco, A. Pappa & M.I. Panayiotidis. (2022) Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. Pharmacology & Therapeutics 240, pages 108301.
Crossref
Crossref
Lin Zhu, Qin Yang, Rong Hu, Yanan Li, Yuanliang Peng, Hong Liu, Mao Ye, Bin Zhang, Peihe Zhang, Feng Liu-Smith, Hui Li & Jing Liu. (2022) Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib. Scientific Reports 12:1.
Crossref
Crossref
Mohammed Boulhaoua, Tibor Pasinszki, Ana Torvisco, Rita Oláh-Szabó, Szilvia Bősze & Antal Csámpai. (2021)
Synthesis, structure and
in vitro
antiproliferative effects of alkyne-linked 1,2,4-thiadiazole hybrids including erlotinib- and ferrocene-containing derivatives
. RSC Advances 11:46, pages 28685-28697.
Crossref
Crossref
Paula Martínez-Fernández, Patricia Pose, Raquel Dolz-Gaitón, Arantxa García, Inmaculada Trigo-Sánchez, Enrique Rodríguez-Zarco, MJose Garcia-Ruiz, Ibon Barba, Marta Izquierdo-García, Jennifer Valero-Garcia, Carlos Ruiz, Marián Lázaro, Paula Carbonell, Pablo Gargallo, Carlos Méndez, Juan José Ríos-Martín, Alberto Palmeiro-Uriach, Natalia Camarasa-Lillo, Jerónimo Forteza-Vila & Inés Calabria. (2021) Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors. Journal of Personalized Medicine 11:5, pages 360.
Crossref
Crossref
Jiangnan Dong, Su Li & Guangxuan Liu. (2021) Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2. Chemical Research in Toxicology 34:4, pages 1169-1174.
Crossref
Crossref
Nicolas Dumaz & Céleste Lebbé. (2021) New perspectives on targeting RAF, MEK and ERK in melanoma. Current Opinion in Oncology 33:2, pages 120-126.
Crossref
Crossref
Ioannis Anestopoulos, Sotiris Kyriakou, Venetia Tragkola, Ioannis Paraskevaidis, Eleni Tzika, Melina Mitsiogianni, Maria Deligiorgi, Giorgos Petrakis, Dimitrios T. Trafalis, Sotiris Botaitis, Alexandra Giatromanolaki, Michail I. Koukourakis, Franco Rodrigo, Aglaia Pappa & Mihalis Panagiotidis. (2022) Targeting the Epigenome in Malignant Melanoma: Facts, Challenges and Therapeutic Promises. SSRN Electronic Journal.
Crossref
Crossref